Chardan Capital Markets Starts Asterias Biotherapeutics (AST) at Buy
Tweet Send to a Friend
Chardan Capital Markets initiated coverage on Asterias Biotherapeutics (NYSE: AST) with a Buy rating and a price target of $5.50 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
